Gilead Sciences (GILD) PT Lowered to $95 at Credit Suisse on Lower HCV Revenue, Visibility

September 14, 2016 6:48 AM EDT
Get Alerts GILD Hot Sheet
Price: $71.01 -0.78%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade GILD Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Credit Suisse analyst Alethia Young lowered her price target on Gilead Sciences (NASDAQ: GILD) to $95 from $115 but maintained an Outperform rating. Young said visibility on HCV is low but HIV and pipeline keeps them positive.

"GILD shares are down 22% this year mostly due to questions around what are sustainable levels for their HCV franchise," Young commented. "We are lowering our HCV revenues because we think street estimates are still too high considering continued price and market share pressure. We are maintaining our Outperform and take a long-term view that at this level any success or greater confidence in pipeline is upside. We see floor values on GILD shares of $60-$70/sh based on HIV value & our thoughts on HCV worst case scenarios. Our new $95/sh TP is based fully on a DCF valuation for GILD vs. split between DCF & multiple previously."

The firm thinks HCV consensus is still too high and are $2B below consensus in 2020.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $78.06 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, FDA

Related Entities

Credit Suisse

Add Your Comment